글로벌 전립선암 항원 3(PCA3) 검사 시장 – 2029년까지의 산업 동향 및 예측

 전립선암 항원 3(PCA3) 검사 시장 분석 및 규모

전립선암 항원 3(PCA3) 검사는 전립선에서만 생성되는 유전 물질(메신저 RNA(mRNA))을 찾습니다. 정상적인 전립선 조직에서는 단백질 PCA3와 관련 mRNA가 낮은 수준으로 존재합니다. PCA3는 전립선암의 약 90%에서 고농도(과발현)로 발견됩니다. 전립선 특이 항원(PSA)도 전립선암에서 증가하지만 다양한 양성 질환에서도 증가할 수 있습니다. 이 검사는 직장 검사(DRE) 후 얻은 첫 번째 소변 샘플에서 PCA3 mRNA와 PSA mRNA를 검출합니다. PCA3 점수는 실험실에서 보고하며 PCA3 mRNA와 PSA mRNA의 비율을 기반으로 합니다.

Data Bridge Market Research는 2021년에 32억 달러였던 전립선암 항원 3(PCA3) 검사 시장이 2029년까지 76억 4천만 달러에 도달할 것으로 분석했으며, 2022년부터 2029년까지의 예측 기간 동안 CAGR은 11.50%가 될 것으로 예상합니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

전립선암 항원 3(PCA3) 검사 시장 범위 및 세분화  

Market Definition

The prostate cancer antigen 3 gene (PCA3) test is used to assess your risk of developing prostate cancer. It is not used to make a diagnosis of prostate cancer. It is primarily used to determine whether your elevated prostate-specific antigen (PSA) levels are the result of prostate cancer. Prostate cancer is a type of cancer that develops in the prostate gland of men and is increasing at a significant rate each year. This cancer is commonly found in the elderly population, and it can have serious consequences such as blood in the sperm, bone pain, and erectile dysfunction, among others. As a result, early detection is required to avoid it at an early stage.

Global Prostate Cancer Antigen 3 (PCA3) Test Market Dynamics

Drivers

• Surging demand for early and precise diagnosis of prostate cancer 

An increase in PSA levels raises the risk of prostate cancer. PSA concentrations in the blood are measured in nanograms per millilitre (ng/mL). There is no clear cut-off point for determining whether a man has prostate cancer or not. Many doctors use a PSA cut-off of 4 ng/mL or higher when determining whether a man requires further testing, while others may be starting at a lower level, such as 2.5 or 3. As a result, measuring PSA levels in a man's blood can help detect prostate cancer early. These are the certain factors which propel the growth of the market.

• Increasing demand for positron emission tomography

Positron emission tomography is increasingly being used as a diagnostic tool because it is more accurate than other diagnostic techniques. The accuracy of diagnosis has a direct impact on decision-making and treatment monitoring processes. Increasing demand for these diagnostic procedures is expected to drive the growth of the prostate cancer antigen 3 (PCA3) test market during the forecast period.

Opportunities

• Government initiatives will improve the growth rate

Increasing government initiatives for technological advancement to improve diagnosis, as well as an increase in the number of new entrants to invest in the market, are expected to drive market growth. Gregor Diagnostics, for example, recently invested USD 900000 to support its effort to develop home screening tests. Furthermore, the increasing demand for early detection and a better diagnostic system is expected to drive market growth.

Restraints/Challenges

• High cost of prostate cancer treatment will restrain the growth

High cost of prostate cancer nuclear medicine diagnostics and the low adoption rate in emerging and underdeveloped countries will obstruct the market's growth rate. There are health risks, because radiation is a side effect of nuclear medicine, prolonged exposure to it can cause health problems. This is especially true for infants, toddlers, elderly and pregnant women.

This prostate cancer antigen 3 (PCA3) test market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the prostate cancer antigen 3 (PCA3) test market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent developments

• In April 2021, Coractive announced an investment of more than USD 24 million in the construction of a cutting-edge fibre optic production facility in Quebec City, Canada.
• In February 2021, Scientific Bioprocessing launched its Intelligent, Dynamic (ID) Fiber Optic Kit. The kit is a pH and dissolved oxygen sensing solution in one that provides real-time, non-invasive, and highly adaptable data from the smallest cell culture systems. It is the first cell monitoring product capable of sensing culture conditions within organ-on-a-chip systems in a reliable manner; it also provides bioprocessing engineers with novel cell culture sensing opportunities.
• In April 2022, Honeywell announced the addition of a blue-hued fibre to its Spectra Medical Grade (MG) Biofiber portfolio, providing a strong visual aid to distinguish between multiple suture sets in complex surgeries. This allows healthcare professionals to operate more accurately by creating clear colour contrast, which can lead to increased patient safety and comfort.

Global Prostate Cancer Antigen 3 (PCA3) Test Market Scope

The prostate cancer antigen 3 (PCA3) test market is segmented on the basis of type of test, technology, end use. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type of Test

• Instruments
• Kits and Reagent
• Consumables
• Molecular
•  Serology

 Technology

• RT-PCR
• ELISA Test
• Micro-neutralization Assays

 End Use

• Hospitals
• Clinics
• Public Health Labs
• Private or Commercial Labs
• Physician Labs
• Research Institutes
• Others

Prostate Cancer Antigen 3 (PCA3) Test Market Regional Analysis/Insights

The prostate cancer antigen 3 (PCA3) test market is analysed and market size insights and trends are provided by country, type of test, technology, end use as referenced above.

The countries covered in the prostate cancer antigen 3 (PCA3) test market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the prostate cancer antigen 3 (PCA3) Test market due to the increasing prevalence of prostate cancer, increasing government initiative to spread awareness about early diagnosis, rising geriatric population are the factors driving the market growth in the region.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to increasing health insurance schemes, rising geriatric population, government initiatives to develop healthcare infrastructure. Moreover, the changing lifestyle is also a factor behind increasing the rate number of patients.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The prostate cancer antigen 3 (PCA3) test market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for prostate cancer antigen 3 (PCA3) Test market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the prostate cancer antigen 3 (PCA3) Test market. The data is available for historic period 2010-2020.

Competitive Landscape and Prostate Cancer Antigen 3 (PCA3) Test Market Share Analysis

전립선암 항원 3(PCA3) 검사 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우위가 있습니다. 위에 제공된 데이터 포인트는 전립선암 항원 3(PCA3) 검사 시장과 관련된 회사의 초점에만 관련이 있습니다.

전립선암 항원 3(PCA3) 검사 시장에서 활동하는 주요 업체는 다음과 같습니다.

• MDxHealth(벨기에)
• Myriad Genetics, Inc. (미국)
• 애벗(미국)
• F. 호프만-라 로슈 유한회사(스위스)
• 지멘스(독일)
• OPKO Health, Inc. (미국)
• 게놈 건강(미국)
• BD(미국)
• Agilent Technologies, Inc. (미국)
• 다나허(미국)

SKU-56078